Biomedicine & Pharmacotherapy (Jun 2024)

Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy

  • Patricia Resa-Infante,
  • Itziar Erkizia,
  • Xabier Muñiz-Trabudua,
  • Federica Linty,
  • Arthur E.H. Bentlage,
  • Daniel Perez-Zsolt,
  • Jordana Muñoz-Basagoiti,
  • Dàlia Raïch-Regué,
  • Nuria Izquierdo-Useros,
  • Theo Rispens,
  • Gestur Vidarsson,
  • Javier Martinez-Picado

Journal volume & issue
Vol. 175
p. 116726

Abstract

Read online

New therapies to treat or prevent viral infections are essential, as recently observed during the COVID-19 pandemic. Here, we propose a therapeutic strategy based on monoclonal antibodies that block the specific interaction between the host receptor Siglec-1/CD169 and gangliosides embedded in the viral envelope. Antibodies are an excellent option for treating infectious diseases based on their high specificity, strong targeting affinity, and relatively low toxicity. Through a process of humanization, we optimized monoclonal antibodies to eliminate sequence liabilities and performed biophysical characterization. We demonstrated that they maintain their ability to block viral entry into myeloid cells. These molecular improvements during the discovery stage are key if we are to maximize efforts to develop new therapeutic strategies. Humanized monoclonal antibodies targeting CD169 provide new opportunities in the treatment of infections caused by ganglioside-containing enveloped viruses, which pose a constant threat to human health. In contrast with current neutralizing antibodies that bind antigens on the infectious particle, our antibodies can prevent several types of enveloped viruses interacting with host cells because they target the host CD169 protein, thus becoming a potential pan-antiviral therapy.

Keywords